You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHyoscyamine
Accession NumberDB00424  (APRD00607)
TypeSmall Molecule
GroupsApproved
DescriptionHyoscyamine is a chemical compound, a tropane alkaloid it is the levo-isomer to atropine. It is a secondary metabolite of some plants, particularly henbane (Hyoscamus niger.) Hyoscyamine is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, pancreatitis, colic and cystitis. It has also been used to relieve some heart problems, control some of the symptoms of Parkinson's disease, as well as for control of respiratory secretions in end of life care.
Structure
Thumb
Synonyms
(-)-Atropine
(-)-Hyoscyamine
(−)-atropine
(−)-hyoscyamine
(S)-(-)-Hyoscyamine
(S)-(−)-hyoscyamine
(S)-atropine
[3(S)-Endo]-alpha-(hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester
Daturin
Daturine
Duboisine
Hyoscyamin
Hyoscyamine
Hyoscyaminum
L-Hyoscyamine
L-Tropine Tropate
Tropine-L-tropate
Tropine, (-)-tropate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LevsinTablet0.125 mgOralSchwarz Pharma Kremers Urban Company1960-12-312008-08-08Canada
Levsin Drops 0.125mg/mlSolution / drops0.125 mgOralSchwarz Pharma Kremers Urban Company1982-12-311996-09-09Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AnaspazTablet, orally disintegrating.125 mg/1Oral; SublingualBF ASCHER AND CO INC1973-01-02Not applicableUs
Ed-spazTablet, orally disintegrating.125 mg/1OralEDWARDS PHARMACEUTICALS, INC.2010-05-12Not applicableUs
HyoscyamineTablet.125 mg/1OralWallace Pharmaceuticals Inc.2016-04-01Not applicableUs
HyoscyamineLiquid.125 mg/mLOralPatrin Pharma2011-09-04Not applicableUs
HyoscyamineLiquid.125 mg/5mLOralPatrin Pharma2011-09-04Not applicableUs
Hyoscyamine ERTablet.375 mg/1OralWallace Pharmaceuticals Inc.2016-05-01Not applicableUs
Hyoscyamine SlTablet, orally disintegrating.125 mg/1OralWallace Pharmaceuticals Inc.2016-04-15Not applicableUs
Hyoscyamine SulfateTablet.125 mg/1Oral; SublingualPd Rx Pharmaceuticals, Inc.2009-09-21Not applicableUs
Hyoscyamine SulfateTablet.375 mg/1OralClinical Solutions Wholesale2009-11-05Not applicableUs
Hyoscyamine SulfateTablet.125 mg/1Oral; SublingualCarilion Materials Management2009-09-21Not applicableUs
Hyoscyamine SulfateTablet.125 mg/1OralDIRECT RX2015-01-01Not applicableUs
Hyoscyamine SulfateTablet.125 mg/1OralAidarex Pharmaceuticals LLC2009-11-05Not applicableUs
Hyoscyamine SulfateTablet.125 mg/1OralProficient Rx LP2009-11-05Not applicableUs
Hyoscyamine SulfateTablet, orally disintegrating.125 mg/1OralAvera Mc Kennan Hospital2015-03-04Not applicableUs
Hyoscyamine SulfateSolution / drops.125 mg/mLOralCypress Pharmaceutical, Inc.2008-12-302016-10-13Us
Hyoscyamine SulfateTablet.125 mg/1OralKmr Pharmaceuticals Llc2011-01-01Not applicableUs
Hyoscyamine SulfateTablet.125 mg/1Oral; SublingualCounty Line Pharmaceuticals, LLC2009-09-21Not applicableUs
Hyoscyamine SulfateElixir.125 mg/5mLOralMethod Pharmaceuticals, Llc2014-11-01Not applicableUs
Hyoscyamine SulfateTablet.125 mg/1Oral; Sublingualbryant ranch prepack2009-09-21Not applicableUs
Hyoscyamine SulfateTablet, orally disintegrating.125 mg/1OralVirtus Pharmaceuticals2011-09-04Not applicableUs
Hyoscyamine SulfateTablet.125 mg/1OralFranklin Pharmaceutical LLC2010-05-01Not applicableUs
Hyoscyamine SulfateTablet.125 mg/1OralKmr Pharmaceuticals Llc2011-01-01Not applicableUs
Hyoscyamine SulfateTablet, orally disintegrating.125 mg/1OralCounty Line Pharmaceuticals, LLC2009-09-21Not applicableUs
Hyoscyamine SulfateSolution.125 mg/mLOralMethod Pharmaceuticals, Llc2014-12-01Not applicableUs
Hyoscyamine SulfateTablet.125 mg/1OralVirtus Pharmaceuticals2011-09-04Not applicableUs
Hyoscyamine SulfateTablet.125 mg/1OralRebel Distributors Corp2009-11-05Not applicableUs
Hyoscyamine SulfateTablet.375 mg/1OralKmr Pharmaceuticals Llc2011-01-01Not applicableUs
Hyoscyamine SulfateTablet.125 mg/1OralCounty Line Pharmaceuticals, LLC2009-11-05Not applicableUs
Hyoscyamine SulfateElixir.125 mg/5mLOralCypress Pharmaceutical, Inc.2008-11-212016-10-13Us
Hyoscyamine SulfateTablet.125 mg/1Oral; SublingualRebel Distributors Corp2009-09-21Not applicableUs
Hyoscyamine SulfateTablet.125 mg/1OralKmr Pharmaceuticals Llc2011-01-01Not applicableUs
Hyoscyamine SulfateTablet.125 mg/1Oral; SublingualProficient Rx LP2009-09-21Not applicableUs
Hyoscyamine SulfateTablet.125 mg/1OralPreferred Pharmaceuticals Inc.2015-10-27Not applicableUs
Hyoscyamine SulfateTablet.375 mg/1OralFranklin Pharmaceutical LLC2010-05-01Not applicableUs
Hyoscyamine Sulfate Extended-releaseTablet.375 mg/1OralCounty Line Pharmaceuticals, LLC2010-01-03Not applicableUs
Hyoscyamine Sulfate Extended-releaseTablet.375 mg/1OralAidarex Pharmaceuticals LLC2010-01-03Not applicableUs
Hyoscyamine Sulfate Extended-releaseTablet.375 mg/1OralCarilion Materials Management2010-01-03Not applicableUs
Hyoscyamine Sulfate Extended-releaseTablet.375 mg/1OralAmerican Health Packaging2015-03-312016-10-25Us
Hyoscyamine Sulfate ODTTablet, orally disintegrating.125 mg/1OralAcella Pharmaceuticals, LLC2011-05-19Not applicableUs
Hyoscyamine Sulfate SlTablet.125 mg/1SublingualAcella Pharmaceuticals, LLC2011-05-19Not applicableUs
Hyoscyamine Sulfate SlTablet.125 mg/1OralREMEDYREPACK INC.2015-08-07Not applicableUs
Hyoscyamine Sulfate SlTablet, soluble.125 mg/1OralFranklin Pharmaceutical LLC2010-05-01Not applicableUs
Hyoscyamine Sulfate SlTablet.125 mg/1OralVirtus Pharmaceuticals2011-09-04Not applicableUs
Hyoscyamine Sulfate TabTablet.125 mg/1OralAcella Pharmaceuticals, LLC2011-05-19Not applicableUs
HyosyneSolution / drops.125 mg/mLOralSilarx Pharmaceuticals, Inc1997-10-01Not applicableUs
HyosyneElixir.125 mg/5mLOralSilarx Pharmaceuticals, Inc1997-11-01Not applicableUs
HyosyneElixir.125 mg/5mLOralAtlantic Biologicals Corp.1997-11-01Not applicableUs
LevbidTablet.375 mg/1OralAlaven Pharmaceutical LLC2008-12-01Not applicableUs
LevsinInjection, solution.5 mg/mLSubcutaneousAlaven Pharmaceutical LLC2008-12-01Not applicableUs
LevsinTablet.125 mg/1OralAlaven Pharmaceutical LLC1955-06-01Not applicableUs
Levsin SlTablet, orally disintegrating.125 mg/1OralAlaven Pharmaceutical LLC2008-12-01Not applicableUs
NulevTablet, chewable.125 mg/1OralAlaven Pharmaceutical LLC2008-12-01Not applicableUs
OsciminTablet, orally disintegrating.125 mg/1SublingualLarken Laboratories, Inc.2011-08-03Not applicableUs
OsciminTablet, orally disintegrating.125 mg/1OralLarken Laboratories, Inc.2011-08-03Not applicableUs
OsciminTablet, extended release.375 mg/1OralLarken Laboratories, Inc.2011-08-03Not applicableUs
OsciminTablet.125 mg/1OralLarken Laboratories, Inc.2011-08-03Not applicableUs
Symax DuotabTablet, multilayer, extended release.375 mg/1OralCapellon Pharmaceuticals, LLC2009-11-07Not applicableUs
Symax FastabTablet, orally disintegrating.125 mg/1OralCapellon Pharmaceuticals, LLC2003-11-012015-12-29Us
Symax SlTablet, orally disintegrating.125 mg/1OralCapellon Pharmaceuticals, LLC1996-09-01Not applicableUs
Symax SRTablet, extended release.375 mg/1OralCapellon Pharmaceuticals, LLC2009-11-07Not applicableUs
International Brands
NameCompany
AcupazGlitz
AnapazHilton
AnaspazAscher
AtropenNot Available
Boots Travel CalmBoots
BuweconYung Shin
CystospazNot Available
CytospazAmerifit
DonnamarNot Available
EgazilBioPhausia
LevbidNot Available
LevsinexNot Available
NuLevNot Available
SymaxCapellon
Brand mixtures
NameLabellerIngredients
Azuphen MbBurel Pharmaceuticals, Inc
B-donnaWinder Laboratories, LLC
Belladonna Alkaloids With PhenobartbitalLiberty Pharmaceuticals, Inc.
Calmitol Itching Relief OntPfizer Canada Inc., Consumer Healthcare Division
Diban CapAyerst Laboratories
Donnagel LiqAyerst Laboratories
DonnatalRebel Distributors Corp
Donnatal ElixirAyerst Laboratories
Donnatal ExtentabsPBM Pharmaceuticals, Inc
Donnatal Extentabs SrtWyeth Ayerst Canada Inc.
Donnatal TabWyeth Ayerst Canada Inc.
Hyolev MbBurel Pharmaceuticals, Inc
HyophenStar Pharmaceuticals, Llc
Indiomin MbBurel Pharmaceuticals, Inc
Me Naphos Mb Hyo 1Method Pharmaceuticals
Me-PB-hyosMethod Pharmaceuticals, Llc
PhenohytroWinder Laboratories, LLC
PhosphasalStar Pharmaceuticals, Llc
QuadrapaxRebel Distributors Corp
Re-PB Hyos ElixirKAISER FOUNDATION HOSPITALS
Se-donna Pb HyosSeton Pharmaceuticals
Ur N-C Urinary AntisepticMayne Pharma Inc.
UralgicWestminster
Uramit MbBurel Pharmaceuticals, Inc
UrelleMeda Pharmaceuticals Inc.
UribelStar Pharmaceuticals, Llc
Urimar-TMarnel Pharmaceutical, Inc.
Urin D/sLlorens Pharmaceutical International Division
Uro-458Method Pharmaceuticals, Llc
Uro-LMethod Pharmaceuticals, Llc
Uro-MPMethod Pharmaceuticals, Llc
Uroav-81Av Kare, Inc.
Uroav-BAv Kare, Inc.
Urogesic BlueEdwards Pharmaceutical, Inc.
Urolet MbBurel Pharmaceuticals, Inc
Urophen MbBurel Pharmaceuticals, Inc
UstellStar Pharmaceuticals Llc
UtaSj Pharmaceuticals, Llc
Utira-CMission Pharmacal Company
Salts
Name/CASStructureProperties
Hyoscyamine hydrobromide
ThumbNot applicableDBSALT001048
Hyoscyamine sulfate
620-61-1
ThumbNot applicableDBSALT001011
Categories
UNIIPX44XO846X
CAS number101-31-5
WeightAverage: 289.3694
Monoisotopic: 289.167793607
Chemical FormulaC17H23NO3
InChI KeyRKUNBYITZUJHSG-FXUDXRNXSA-N
InChI
InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15+,16-/m1/s1
IUPAC Name
(1R,3R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl (2S)-3-hydroxy-2-phenylpropanoate
SMILES
CN1[[email protected]]2CC[C@@H]1C[C@@H](C2)OC(=O)[[email protected]](CO)C1=CC=CC=C1
Pharmacology
IndicationFor treatment of bladder spasms, peptic ulcer disease, diverticulitis, colic, irritable bowel syndrome, cystitis, and pancreatitis. Also used to treat certain heart conditions, to control the symptoms of Parkinson's disease and rhinitis.
Structured Indications
PharmacodynamicsL-Hyoscyamine, the active optical isomer of atropine (dl-hyoscyamine), is a tertiary amine anticholinergic gastrointestinal agent.
Mechanism of actionHyoscyamine competes favorably with acetylcholine for binding at muscarinic receptors in the salivary, bronchial, and sweat glands as well as in the eye, heart, and gastrointestinal tract. The actions of hyoscyamine result in a reduction in salivary, bronchial, gastric and sweat gland secretions, mydriasis, cycloplegia, change in heart rate, contraction of the bladder detrusor muscle and of the gastrointestinal smooth muscle, and decreased gastrointestinal motility.
TargetKindPharmacological actionActionsOrganismUniProt ID
Muscarinic acetylcholine receptor M1Proteinyes
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinyes
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinunknown
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M4Proteinunknown
antagonist
HumanP08173 details
Related Articles
AbsorptionAbsorbed totally and completely by sublingual administration as well as oral administration.
Volume of distributionNot Available
Protein binding50%
Metabolism

Hepatic

Route of eliminationNot Available
Half life2-3.5 hours
ClearanceNot Available
ToxicitySymptoms of overdose include headache, nausea, vomiting, blurred vision, dilated pupils, hot dry skin, dizziness, dryness of the mouth, difficulty in swallowing, and CNS stimulation. LD50=mg/kg(orally in rat)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumAclidinium may increase the anticholinergic activities of Hyoscyamine.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Alphacetylmethadol.Experimental, Illicit
Aluminum hydroxideThe serum concentration of Hyoscyamine can be decreased when it is combined with Aluminum hydroxide.Approved
Aluminum phosphateThe serum concentration of Hyoscyamine can be decreased when it is combined with Aluminum phosphate.Approved
AmbenoniumThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Ambenonium.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Anisotropine Methylbromide.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Atropine.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Hyoscyamine.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Hyoscyamine.Approved
BezitramideThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Biperiden.Approved
Bismuth SubcitrateThe serum concentration of Hyoscyamine can be decreased when it is combined with Bismuth Subcitrate.Approved
Botulinum Toxin Type AHyoscyamine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BHyoscyamine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Butorphanol.Approved, Illicit, Vet Approved
Calcium carbonateThe serum concentration of Hyoscyamine can be decreased when it is combined with Calcium carbonate.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Carfentanil.Illicit, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Hyoscyamine.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Chlorphenoxamine.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Hyoscyamine.Approved
CimetropiumHyoscyamine may increase the anticholinergic activities of Cimetropium.Experimental
CodeineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Coumaphos.Vet Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Cyclopentolate.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Darifenacin.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Desloratadine.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dexetimide.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dezocine.Approved
DichlorvosThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dicyclomine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dihydromorphine.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Diphenoxylate.Approved, Illicit
DonepezilThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Donepezil.Approved
DPDPEThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with DPDPE.Investigational
DronabinolHyoscyamine may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Edrophonium.Approved
EluxadolineHyoscyamine may increase the constipating activities of Eluxadoline.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Hyoscyamine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Etorphine.Illicit, Vet Approved
FentanylThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Fesoterodine.Approved
GalantamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Gallamine Triethiodide.Approved
Ginkgo bilobaThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Glucagon recombinant.Approved
GlycopyrroniumHyoscyamine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Hyoscyamine.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Hyoscyamine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Hydromorphone.Approved, Illicit
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Hyoscyamine.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hyoscyamine.Approved
IsoflurophateThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Hyoscyamine.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Ketobemidone.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Lofentanil.Illicit
MagaldrateThe serum concentration of Hyoscyamine can be decreased when it is combined with Magaldrate.Withdrawn
Magnesium carbonateThe serum concentration of Hyoscyamine can be decreased when it is combined with Magnesium carbonate.Approved
Magnesium hydroxideThe serum concentration of Hyoscyamine can be decreased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Hyoscyamine can be decreased when it is combined with Magnesium oxide.Approved
Magnesium TrisilicateThe serum concentration of Hyoscyamine can be decreased when it is combined with Magnesium Trisilicate.Approved
MalathionThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Malathion.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Mecamylamine.Approved
MefloquineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Memantine.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Methantheline.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Hyoscyamine.Approved
MetixeneThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Metixene.Approved
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Hyoscyamine.Approved
MianserinMianserin may increase the anticholinergic activities of Hyoscyamine.Approved
MinaprineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Morphine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with N-butylscopolammonium bromide.Vet Approved
NabiloneHyoscyamine may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Normethadone.Approved, Illicit
NVA237The risk or severity of adverse effects can be increased when Hyoscyamine is combined with NVA237.Investigational
OpiumThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Orphenadrine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Hyoscyamine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pancuronium.Approved
PentazocineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pentolinium.Approved
PethidineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pethidine.Approved
PhysostigmineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pipecuronium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pirenzepine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Hyoscyamine.Approved
Potassium ChlorideHyoscyamine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Hyoscyamine.Approved, Investigational
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Hyoscyamine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Propantheline.Approved
PropiverineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Propiverine.Investigational
PyridostigmineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Hyoscyamine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Quinidine.Approved
RamosetronHyoscyamine may increase the constipating activities of Ramosetron.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Remifentanil.Approved
RivastigmineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Scopolamine butylbromide.Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Hyoscyamine.Approved, Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Solifenacin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Hyoscyamine.Approved
TacrineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Tacrine.Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Tapentadol.Approved
TiotropiumHyoscyamine may increase the anticholinergic activities of Tiotropium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Hyoscyamine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Hyoscyamine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Trimethaphan.Approved
TropicamideThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Tropicamide.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Hyoscyamine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Hyoscyamine.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Vecuronium.Approved
Food Interactions
  • Take 30 minutes before meals, and at bedtime.
References
Synthesis Reference

Jeffrey Kiel, H. Thomas, Emily Ware, Brady Ware, “Phenolic acid complexes of hyoscyamine and process for preparing the same.” U.S. Patent US20060128637, issued June 15, 2006.

US20060128637
General ReferencesNot Available
External Links
ATC CodesA03CB31A03BA03
AHFS Codes
  • 12:08.08
  • 92:02.00*
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9286
Blood Brain Barrier+0.9569
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.6542
P-glycoprotein inhibitor IINon-inhibitor0.8595
Renal organic cation transporterInhibitor0.7956
CYP450 2C9 substrateNon-substrate0.7041
CYP450 2D6 substrateNon-substrate0.6838
CYP450 3A4 substrateSubstrate0.5496
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9275
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9285
CYP450 3A4 inhibitorNon-inhibitor0.95
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9113
Ames testNon AMES toxic0.7742
CarcinogenicityNon-carcinogens0.9631
BiodegradationReady biodegradable0.5527
Rat acute toxicity2.7305 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8354
hERG inhibition (predictor II)Inhibitor0.5378
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tablet, orally disintegratingOral; Sublingual.125 mg/1
TabletOral
OintmentTopical
CapsuleOral
LiquidOral
Tablet, extended releaseOral
Tablet, film coated, extended releaseOral
Tablet, orally disintegratingOral.125 mg/1
LiquidOral.125 mg/mL
LiquidOral.125 mg/5mL
SolutionOral.125 mg/mL
TabletOral.125 mg/1
TabletOral; Sublingual.125 mg/1
TabletOral.375 mg/1
TabletSublingual.125 mg/1
Tablet, solubleOral.125 mg/1
ElixirOral.125 mg/5mL
Solution / dropsOral.125 mg/mL
Injection, solutionSubcutaneous.5 mg/mL
TabletOral0.125 mg
Solution / dropsOral0.125 mg
Tablet, chewableOral.125 mg/1
Tablet, extended releaseOral.375 mg/1
Tablet, orally disintegratingSublingual.125 mg/1
ElixirOral
Tablet, multilayer, extended releaseOral.375 mg/1
Tablet, coatedOral
Prices
Unit descriptionCostUnit
Levsin 0.125 mg/ml Solution 15ml Bottle49.09USD bottle
Levsin 0.5 mg/ml ampul27.33USD ml
Hyoscyamine sulfate powder25.69USD g
Symax Duotab 0.375 mg Controlled Release Tabs3.73USD tab
Symax-SL 0.125 mg Sublingual Tabs3.29USD tab
Symax duotab2.4USD tablet
Levbid 0.375 mg 12 Hour tablet2.12USD tablet
Levbid er 0.375 mg tablet2.09USD tablet
Hyoscyamine Sulfate CR 0.375 mg 12 Hour tablet1.66USD tablet
Levbid 0.375 mg tablet sa1.44USD tablet
Symax-sr 0.375 mg tablet1.4USD tablet
Levsin/SL 0.125 mg Sublingual Tabs1.24USD tab
Symax fastabs 0.125 mg tablet1.21USD tablet
Symax-sl 0.125 mg tablet sl1.17USD tablet
Levsin 0.125 mg tablet1.08USD tablet
Levsin-sl 0.125 mg tablet sl0.97USD tablet
Hyoscyamine Sulfate 0.125 mg tablet0.93USD tablet
Nulev 0.125 mg tablet0.91USD tablet
Hyoscyamine Sulfate 0.125 mg Sublingual Tabs0.88USD tab
Hyomax-sl 0.125 mg tablet sl0.86USD tablet
Hyoscyamine Sulfate 0.125 mg Dispersible Tablet0.83USD dispersible tablet
Hyoscyamine sulf 0.125 mg tablet0.79USD tablet
Hyoscyamine su 0.125 mg tablet0.64USD tablet
Hyoscyamine 0.125 mg tablet sl0.53USD tablet
Hyoscyamine sul 0.15 mg tablet sl0.39USD tablet
Anaspaz 0.125 mg Dispersible Tablet0.36USD dispersible tablet
Levsin 0.125 mg/5ml Elixir0.29USD ml
Anaspaz 0.125 mg tablet sl0.26USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point108.5 °CPhysProp
water solubility3560 mg/L (at 20 °C)MERCK INDEX (1996); pH 9.5
logP1.8Not Available
logS-1.91ADME Research, USCD
pKa11.7MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility2.52 mg/mLALOGPS
logP2.19ALOGPS
logP1.57ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)15.15ChemAxon
pKa (Strongest Basic)9.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity80.82 m3·mol-1ChemAxon
Polarizability31.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.14 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00di-9810000000-bdd60b3a23f97899d426View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylacetic acid derivatives. These are compounds containing a phenylacetic acid moiety, which consists of a phenyl group substituted at the second position by an acetic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylacetic acid derivatives
Direct ParentPhenylacetic acid derivatives
Alternative Parents
Substituents
  • Phenylacetate
  • Tropane alkaloid
  • Beta-hydroxy acid
  • N-alkylpyrrolidine
  • Piperidine
  • Hydroxy acid
  • Pyrrolidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Huang XP, Williams FE, Peseckis SM, Messer WS Jr: Pharmacological characterization of human m1 muscarinic acetylcholine receptors with double mutations at the junction of TM VI and the third extracellular domain. J Pharmacol Exp Ther. 1998 Sep;286(3):1129-39. [PubMed:9732369 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Lysikova M, Havlas Z, Tucek S: Interactions between allosteric modulators and 4-DAMP and other antagonists at muscarinic receptors: potential significance of the distance between the N and carboxyl C atoms in the molecules of antagonists. Neurochem Res. 2001 Apr;26(4):383-94. [PubMed:11495349 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Lysikova M, Havlas Z, Tucek S: Interactions between allosteric modulators and 4-DAMP and other antagonists at muscarinic receptors: potential significance of the distance between the N and carboxyl C atoms in the molecules of antagonists. Neurochem Res. 2001 Apr;26(4):383-94. [PubMed:11495349 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Lysikova M, Havlas Z, Tucek S: Interactions between allosteric modulators and 4-DAMP and other antagonists at muscarinic receptors: potential significance of the distance between the N and carboxyl C atoms in the molecules of antagonists. Neurochem Res. 2001 Apr;26(4):383-94. [PubMed:11495349 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23